A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs LY 3009120 (Primary)
- Indications Cancer metastases; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Tumours
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 20 Oct 2017 Planned End Date changed from 1 Nov 2017 to 1 May 2018.
- 21 Jul 2017 Planned End Date changed from 7 Jul 2017 to 1 Nov 2017.
- 02 Jun 2017 Results (n=34; data cut off: 2 Jan 2016) assessing safety and tolerabilty presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History